AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Laparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer

RecruitingNAAges any - anyAllJilin University
💬

In plain words

What the trial is, and whether it could suit you

This study is to evaluate the safety and efficacy of dual-endoscope assisted sentinel lymph node navigation surgery for early gastric cancer (EGC).

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Preoperative assessment indicating that the tumor was confined to the mucosa or submucosa, consistent with the diagnosis of early gastric cancer. * Patients who required additional surgical intervention following initial endoscopic submucosal dissection (ESD) based on postoperative pathological evaluation. * Patients and their families fully understood the procedure, requested dual-endoscope assisted sentinel lymph node navigation surgery, agreed to participate in this clinical study, and signed the informed consent form. Exclusion Criteria: * Preoperative assessment indicating suspected lymph node or distant metastasis. * History of complex abdominal surgery rendering laparoscopic treatment infeasible. * Participation in another clinical trial within 4 weeks prior to enrollment or currently participating in another trial. * History of severe psychiatric disorders. * Pregnant or lactating women. * Uncontrolled infection prior to surgery. * Presence of other malignancies or comorbidities that may significantly affect survival. * Any other conditions deemed by the investigators as unsuitable for participation, or refusal by the patient or family to enroll. * Cardiopulmonary, hepatic, and renal functions were unsufficient to tolerate the surgery.
💊

What it tests

  • Laparoscopic-endoscopic cooperative surgery (LECS) Assisted Sentinel Lymph Node Navigation Surgery
📍

Where

2 sites
the First Hospital of Jilin University
Changchun, China
the First Hospital of Jilin University
Ch’ang-ch’un, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy